» Articles » PMID: 30906639

Genetic Ablation of Mammary Ducts Through Foxa1 Prevents Breast Cancer Occurrence

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2019 Mar 26
PMID 30906639
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Risk reducing mastectomy is the only surgical approach for the prevention of breast cancer in women with deleterious genetic mutations or in those deemed to be at extremely high risk. However, up to 10.5% of these women still developed breast cancer. Thus, developing new strategies for complete prevention of breast cancer is imperative. Mammary ducts were ablated by mammary-specific ablation of forkhead box protein A1 (Foxa1). Mammary tumorigenesis was induced in control and mammary-specific Foxa1 knockout mice using carcinogens. No mammary tumors were observed in these knockout mice compared to four types of breast tumors induced in control mice. We present a promising novel strategy for the prevention of breast cancer by genetic ablation of mammary ducts via targeting Foxa1.

Citing Articles

Deletion of in the mouse mammary gland results in abnormal accumulation of luminal progenitor cells: a link between reproductive factors and ER-/TNBC breast cancer?.

Sribenja S, Maguire O, Attwood K, Buas M, Palmer J, Ambrosone C Am J Cancer Res. 2021; 11(6):3263-3270.

PMID: 34249460 PMC: 8263678.

References
1.
Peralta E, Ellenhorn J, Wagman L, Dagis A, Andersen J, Chu D . Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2001; 180(6):439-45. DOI: 10.1016/s0002-9610(00)00505-5. View

2.
McDonnell S, Schaid D, Myers J, Grant C, Donohue J, Woods J . Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001; 19(19):3938-43. DOI: 10.1200/JCO.2001.19.19.3938. View

3.
Rebbeck T, Friebel T, Lynch H, Neuhausen S, van t Veer L, Garber J . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22(6):1055-62. DOI: 10.1200/JCO.2004.04.188. View

4.
Quan G, Pommier S, Pommier R . Incidence and outcomes of contralateral breast cancers. Am J Surg. 2008; 195(5):645-50. DOI: 10.1016/j.amjsurg.2008.01.007. View

5.
Gao N, LeLay J, Vatamaniuk M, Rieck S, Friedman J, Kaestner K . Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 2009; 22(24):3435-48. PMC: 2607077. DOI: 10.1101/gad.1752608. View